CDK9 inhibitors in acute myeloid leukemia

Silvia Boffo, Angela Damato, Luigi Alfano, Antonio Giordano

Research output: Contribution to journalReview articlepeer-review


Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.

Original languageEnglish
Article number36
JournalJournal of Experimental and Clinical Cancer Research
Issue number1
Publication statusPublished - Feb 23 2018


  • Acute myeloid leukemia
  • CDK9 inhibitor
  • MCL-1
  • MYC
  • P-TEFb
  • Positive transcription elongation factor b

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'CDK9 inhibitors in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this